AEGiS-14IAC: Mean cell volume changes in hiv positive patients taking nucleoside reverse trascritase inhibitors: A surrogate marker for adherence.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Mean cell volume changes in hiv positive patients taking nucleoside reverse trascritase inhibitors: A surrogate marker for adherence.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10172)

Steele RH, Keogh GL, Quin JW, Fernando SL, Stojkova V
Bigge Park Centre, Liverpool, Australia

BACKGROUND: Poor adherence is an important factor in drug treatment failure. Monitoring adherence in a clinical setting is practically difficult. This study assessed the utility of changes in mean red cell volume (MCV)as a surrogate marker of adherence to nucleoside analogues in combination antiretroviral therapy.

METHODS: Patients were retrospectively reviewed. All mean red cell volumes and medications dispensed, including the numbers of days, were collected. The days of medications dispensed over the actual time elapsed was used as a marker of adherence. For each MCV the adherence based on prescriptions dispensed for the previous 24 weeks was calculated.

RESULTS: A total of 72 of 82 subjects analysed were eligible for the study. The MCV was found to progressively rise over the first 20-24 weeks then stabilize at set point. The correlation between zidovudine and stavudine adherence based on prescriptions was 0.92 and 0.81 respectively (p<0.05 for both). When adherence was categorised into 10% intervals, there was a progressive rise in the average MCV with increasing adherence that plateaus at approximately 70% adherence. Plotting % MCV rise on time charts appears to detect those subjects with adherence less than 70%.

CONCLUSIONS: Changes in MCV for HIV positive patients taking either zidovudine or stavudine appears to be useful as a tool to predict those patients with poor adherence

Keywords: AEGIS, HIV Infections, Stavudine, Erythrocyte Indices, Zidovudine, HIV, Anti-HIV Agents, Biological Markers, HIV Protease Inhibitors, HIV Seropositivity, Treatment Failure, HumanKWDaegis,hivinfections,stavudine,erythrocyteindices,zidovudine,hiv,anti-hivagents,biologicalmarkers,hivproteaseinhibitors,hivseropositivity,treatmentfailure,human

020707
B10172

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.